Intellia Therapeutics, Inc. (NTLA)
12.68
-0.04
(-0.35%)
USD |
NASDAQ |
Sep 01, 16:00
12.68
0.00 (0.00%)
After-Hours: 06:38
Intellia Therapeutics Research and Development Expense (Annual) : 379.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 379.09M |
| December 31, 2024 | 456.03M |
| December 31, 2023 | 426.09M |
| December 31, 2022 | 412.41M |
| December 31, 2021 | 222.92M |
| December 31, 2020 | 144.10M |
| Date | Value |
|---|---|
| December 31, 2019 | 108.41M |
| December 31, 2018 | 89.12M |
| December 31, 2017 | 67.65M |
| December 31, 2016 | 31.84M |
| December 31, 2015 | 11.17M |
| December 31, 2014 | 1.105M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Beam Therapeutics, Inc. | 409.62M |
| Twist Bioscience Corp. | 80.28M |
| Tenaya Therapeutics, Inc. | 68.61M |
| Moderna, Inc. | 2.917B |
| Revolution Medicines, Inc. | 978.68M |